Fierce Pharma
OCTOBER 21, 2023
Exelixis touted last month that its Cabometyx proved so successful in neuroendocrine tumors that the trial ended early. | Exelixis touted last month that its Cabometyx proved so successful in neuroendocrine tumors that the trial ended early. Now, we get to see what one analyst had already heralded as the “dramatic improvements” at the ESMO Congress.
Drug Patent Watch
OCTOBER 21, 2023
This chart shows the pharmaceutical companies with the most patents in Luxembourg. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Luxembourg? appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
OCTOBER 21, 2023
After two immunotherapies demonstrated their power against endometrial cancer, AstraZeneca now suggests that adding Merck-partnered Lynparza to its Imfinzi may offer another option. | After two immunotherapies demonstrated their power against endometrial cancer, AstraZeneca now suggests that adding Merck-partnered Lynparza to its Imfinzi may offer another option.
Drug Patent Watch
OCTOBER 21, 2023
Sugammadex sodium is the generic ingredient in two branded drugs marketed by Msd Sub Merck, Aspiro, Mylan, and Sandoz and, and is included in four NDAs. There is one patent… The post New tentative approval for MYLAN drug sugammadex sodium appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Pharma
OCTOBER 21, 2023
Bladder cancer hasn’t been the easiest tumor type to tackle for immunotherapies. Bristol Myers Squibb has found success here with its Opdivo, but the win was overshadowed by competitor data. | Bladder cancer hasn't been the easiest tumor type to tackle for immunotherapies. Bristol Myers Squibb has found success here with its Opdivo, but the win was overshadowed by Keytruda and Padcev's competitor data.
Drug Patent Watch
OCTOBER 21, 2023
Sugammadex sodium is the generic ingredient in two branded drugs marketed by Msd Sub Merck, Aspiro, Mylan, and Sandoz and, and is included in four NDAs. There is one patent… The post New tentative approval for Sandoz drug sugammadex sodium appeared first on DrugPatentWatch - Make Better Decisions.
ECRG Media's Clinical Research Podcast
OCTOBER 21, 2023
Will CRA's have Jobs? Found this episode in the hard drive and forgot to upload it. It is still as relevent today. What do you think will be the future of the CRA role? Don't forget to Subscribe for new content! Merch: [link] Subscribe: / eliteclinicalresearch Email: eliteclinicalgroup@gmail.com Podcast: [link] Steemit: [link] Advertise: eliteclinicalgroup@gmail.com Watch: » Industry News: [link] » All Videos: [link] » Interview Recaps: [link] » Glassdoor Reviews: [link] We do: » In
Expert insights. Personalized for you.
105 
Let's personalize your content